{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer+Patients&page=18", "query": { "condition": "Prostate Cancer Patients", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 1891, "total_pages": 190, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer+Patients&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer+Patients&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T08:16:38.198Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05199584", "title": "A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors With PTCH1 Loss-of-function Mutations" ], "interventions": [ { "name": "ENV-101 (taladegib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Endeavor Biomedicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2022-05-24", "completion_date": "2024-02-20", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-10-31T08:16:38.198Z", "location_count": 16, "location_summary": "Los Angeles, California • Santa Rosa, California • Tampa, Florida + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Zion", "state": "Illinois" }, { "city": "Covington", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05199584" }, { "nct_id": "NCT03450109", "title": "A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer of Prostate" ], "interventions": [ { "name": "LY01005", "type": "DRUG" }, { "name": "Zoladex", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Luye Pharma Group Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 19, "start_date": "2017-12-22", "completion_date": "2018-10-30", "has_results": false, "last_update_posted_date": "2019-01-07", "last_synced_at": "2026-10-31T08:16:38.198Z", "location_count": 5, "location_summary": "Anniston, Alabama • Aventura, Florida • Pompano Beach, Florida + 2 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Aventura", "state": "Florida" }, { "city": "Pompano Beach", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03450109" }, { "nct_id": "NCT01468532", "title": "Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adenocarcinoma of the Prostate", "Hormone-resistant Prostate Cancer", "Recurrent Prostate Cancer", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "pasireotide", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 18, "start_date": "2011-10", "completion_date": "2017-07-20", "has_results": true, "last_update_posted_date": "2021-03-25", "last_synced_at": "2026-10-31T08:16:38.198Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01468532" }, { "nct_id": "NCT01519414", "title": "Tivantinib in Treating Patients With Metastatic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hormone-Resistant Prostate Cancer", "Prostate Adenocarcinoma", "Recurrent Prostate Carcinoma", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Tivantinib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 78, "start_date": "2012-01-11", "completion_date": "2015-08-18", "has_results": true, "last_update_posted_date": "2018-09-12", "last_synced_at": "2026-10-31T08:16:38.198Z", "location_count": 20, "location_summary": "Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 14 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01519414" }, { "nct_id": "NCT01228084", "title": "Sulforaphane in Treating Patients With Recurrent Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Prostate", "Recurrent Prostate Cancer" ], "interventions": [ { "name": "Sulforaphane", "type": "DRUG" }, { "name": "Laboratory biomarker analysis", "type": "OTHER" }, { "name": "Pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 20, "start_date": "2010-11", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2017-04-28", "last_synced_at": "2026-10-31T08:16:38.198Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01228084" }, { "nct_id": "NCT02009449", "title": "A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Prostate Cancer", "Ovarian Cancer", "Renal Cell Carcinoma", "Colorectal Carcinoma", "Pancreatic Carcinoma", "Non-small Cell Lung Carcinoma", "Solid Tumors", "Breast Cancer" ], "interventions": [ { "name": "Pegilodecakin", "type": "DRUG" }, { "name": "Paclitaxel or Docetaxel and Carboplatin or Cisplatin", "type": "DRUG" }, { "name": "FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)", "type": "DRUG" }, { "name": "gemcitabine/nab-paclitaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Pazopanib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "nivolumab", "type": "DRUG" }, { "name": "Gemcitabine/carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 353, "start_date": "2013-11-15", "completion_date": "2023-07-22", "has_results": true, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-10-31T08:16:38.198Z", "location_count": 10, "location_summary": "Los Angeles, California • San Francisco, California • Denver, Colorado + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02009449" }, { "nct_id": "NCT00017576", "title": "Calcitriol and Carboplatin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "calcitriol", "type": "DIETARY_SUPPLEMENT" }, { "name": "carboplatin", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "MALE", "summary": "18 Years to 120 Years · Male only" }, "enrollment_count": 19, "start_date": "2000-12", "completion_date": "2006-07", "has_results": false, "last_update_posted_date": "2017-04-28", "last_synced_at": "2026-10-31T08:16:38.198Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00017576" }, { "nct_id": "NCT02737332", "title": "A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Zytiga® (Abiraterone Acetate)", "type": "DRUG" }, { "name": "SoluMatrix™ (Abiraterone Acetate)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sun Pharmaceutical Industries Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 53, "start_date": "2016-03-21", "completion_date": "2017-02-27", "has_results": true, "last_update_posted_date": "2021-11-22", "last_synced_at": "2026-10-31T08:16:38.198Z", "location_count": 17, "location_summary": "Laguna Hills, California • Los Angeles, California • San Bernardino, California + 14 more", "locations": [ { "city": "Laguna Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Bernardino", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Whittier", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02737332" }, { "nct_id": "NCT01162395", "title": "Open Label Prostate Cancer Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "AZD3514", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "20 Years", "maximum_age": "130 Years", "sex": "MALE", "summary": "20 Years to 130 Years · Male only" }, "enrollment_count": 64, "start_date": "2010-08", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2016-01-12", "last_synced_at": "2026-10-31T08:16:38.198Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01162395" }, { "nct_id": "NCT04207255", "title": "Addition of Opaganib to Androgen Antagonists in Patients With mCRPC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Opaganib", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 69, "start_date": "2020-03-27", "completion_date": "2024-07-31", "has_results": true, "last_update_posted_date": "2024-09-25", "last_synced_at": "2026-10-31T08:16:38.198Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Charleston, South Carolina", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04207255" } ] }